{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:16:39Z","timestamp":1790640999199,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2018.10.103","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T07:53:13Z","timestamp":1542873193000},"page":"A88-A93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"S1","title":["Evaluating new rabies post-exposure prophylaxis (PEP) regimens or vaccines"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6946-7958","authenticated-orcid":false,"given":"Arnaud","family":"Tarantola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathurin Cyrille","family":"Tejiokem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0699-9903","authenticated-orcid":false,"given":"Deborah J.","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2018.10.103_b0005","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/tbed.12283","article-title":"Towards canine rabies elimination in KwaZulu-Natal, South Africa: assessment of health economic data","volume":"63","author":"Shwiff","year":"2016","journal-title":"Transbound Emerg Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.103_b0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/tbed.12637","article-title":"Towards canine rabies elimination: economic comparisons of three project sites","volume":"65","author":"Elser","year":"2018","journal-title":"Transbound Emerg Dis"},{"key":"10.1016\/j.vaccine.2018.10.103_b0015","doi-asserted-by":"crossref","first-page":"184","DOI":"10.12688\/f1000research.10416.1","article-title":"Lyssaviruses and rabies: current conundrums, concerns, contradictions and controversies","volume":"6","author":"Rupprecht","year":"2017","journal-title":"F1000 Research"},{"issue":"93","key":"10.1016\/j.vaccine.2018.10.103_b0020","first-page":"201","article-title":"WHO position paper \u2013 April 2018","volume":"16","author":"Vaccines","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2018.10.103_b0025","unstructured":"Guidelines on clinical evaluation of vaccines: Regulatory expectations. Replacement of Annex 1 of WHO Technical Report Series, No. 924. 2017, World Health Organization. p. 503\u2013573."},{"key":"10.1016\/j.vaccine.2018.10.103_b0030","doi-asserted-by":"crossref","unstructured":"Rabies vaccines: WHO position paper\u2013recommendations. Vaccine, 2010. 28(44): p. 7140\u20132.","DOI":"10.1016\/j.vaccine.2010.08.082"},{"key":"10.1016\/j.vaccine.2018.10.103_b0035","unstructured":"Rabies vaccines. WHO position paper. Wkly Epidemiol Rec, 2007. 82(49\u201350): p. 425-35."},{"key":"10.1016\/j.vaccine.2018.10.103_b0040","unstructured":"WHO Expert Consultation on Rabies. Second report. World Health Organ Tech Rep Ser, 2013(982): p. 1\u2013139."},{"key":"10.1016\/j.vaccine.2018.10.103_b0045","unstructured":"WHO Expert Consultation on rabies. World Health Organ Tech Rep Ser, 2005. 931: p. 1\u201388."},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.103_b0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/tropicalmed2020005","article-title":"Four thousand years of concepts relating to rabies in animals and humans, Its prevention and its cure","volume":"2","author":"Tarantola","year":"2017","journal-title":"Trop Med Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.103_b0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/187152611795768079","article-title":"Human rabies encephalitis prevention and treatment: progress since Pasteur's discovery","volume":"11","author":"Dacheux","year":"2011","journal-title":"Infect Disord Drug Targets"},{"issue":"11","key":"10.1016\/j.vaccine.2018.10.103_b0060","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1586\/erv.11.140","article-title":"From brain passage to cell adaptation: the road of human rabies vaccine development","volume":"10","author":"Wu","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.103_b0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/153685902317401726","article-title":"Rabies vaccines: from the past to the 21st century","volume":"21","author":"Kammer","year":"2002","journal-title":"Hybrid Hybridomics"},{"key":"10.1016\/j.vaccine.2018.10.103_b0070","unstructured":"WHO Expert Committee on Rabies, in WHO Technical Report Series No. 824:84. 1984, World Health Organization: Geneva. p. 1\u2013150."},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.103_b0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5604\/12321966.1141372","article-title":"Epidemiology of animal bites and other potential rabies exposures and anti-rabies vaccine utilization in a rural area in Southern Ethiopia","volume":"22","author":"Ramos","year":"2015","journal-title":"Ann Agric Environ Med"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.103_b0080","first-page":"561","article-title":"Human pre-exposure rabies immunization with suckling mouse brain vaccine","volume":"46","author":"Fuenzalida","year":"1972","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2018.10.103_b0085","first-page":"1","article-title":"Comparison of the immunogenicity and safety of the purified chick embryo cell rabies vaccine manufactured in India and Germany: a randomized, single blind, multicentre, phase IV clinical study","author":"Sampath","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.103_b0090","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4161\/hv.26756","article-title":"Pre-exposure prophylaxis against rabies in children: safety of purified chick embryo cell rabies vaccine (Vaxirab N) when administered by intradermal route","volume":"10","author":"Ravish","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.103_b0095","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/21645515.2016.1230260","article-title":"Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above","volume":"13","author":"Wang","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"47","key":"10.1016\/j.vaccine.2018.10.103_b0100","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005049","article-title":"Safety comparison of four types of rabies vaccines in patients with WHO category II animal exposure: an observation based on different age groups","volume":"95","author":"Peng","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"10.1016\/j.vaccine.2018.10.103_b0105","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1080\/21645515.2015.1048938","article-title":"Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases","volume":"11","author":"Narayana","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.103_b0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0264-410X(88)90225-3","article-title":"Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment","volume":"6","author":"Vodopija","year":"1988","journal-title":"Vaccine"},{"issue":"51","key":"10.1016\/j.vaccine.2018.10.103_b0115","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1016\/j.vaccine.2009.09.029","article-title":"Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals","volume":"27","author":"Rupprecht","year":"2009","journal-title":"Vaccine"},{"issue":"RR-2","key":"10.1016\/j.vaccine.2018.10.103_b0120","first-page":"1","article-title":"Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices","volume":"59","author":"Rupprecht","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"8694","key":"10.1016\/j.vaccine.2018.10.103_b0125","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/0140-6736(90)90488-Q","article-title":"Postexposure prophylaxis for rabies with antiserum and intradermal vaccination","volume":"335","author":"Chutivongse","year":"1990","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2018.10.103_b0130","first-page":"693","article-title":"Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine","volume":"78","author":"Briggs","year":"2000","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2018.10.103_b0135","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(85)92367-0","article-title":"Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis","volume":"11","author":"Warrell","year":"1985","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.vaccine.2018.10.103_b0140","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1016\/j.vaccine.2006.01.051","article-title":"Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection","volume":"24","author":"Khawplod","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.103_b0145","first-page":"1","article-title":"Multisite intradermal vaccination using tissue culture vaccine as an economical prophylactic regimen against rabies","volume":"87","author":"Madhusudana","year":"1988","journal-title":"Indian J Med Res"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.103_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000224","article-title":"A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods","volume":"2","author":"Warrell","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2018.10.103_b0155","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/jtm.12228","article-title":"Rabies vaccine and rabies immunoglobulin in cambodia: use and obstacles to use","volume":"22","author":"Tarantola","year":"2015","journal-title":"J Travel Med"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.103_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003709","article-title":"Global alliance for rabies control partners for rabies prevention., Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.10.103_b0165","unstructured":"Guideline on clinical evaluation of vaccines. 2018, European Medicines Agency. p. 1\u201321."},{"key":"10.1016\/j.vaccine.2018.10.103_b0170","unstructured":"Annex 9: Guidelines on clinical evaluation of vaccines: regulatory expectations. Replacement of Annex 1 of WHO Technical Report Series, No. 924. 2017, World Health Organization: Geneva. p. 1\u201371."},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.103_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CVI.00531-14","article-title":"Zagreb regimen, an abbreviated intramuscular schedule for rabies vaccination","volume":"22","author":"Ren","year":"2015","journal-title":"Clin Vaccine Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2018.10.103_b0180","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4161\/hv.20471","article-title":"Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: results of a randomized, open label, active-controlled trial in healthy adult volunteers in India","volume":"8","author":"Sudarshan","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.103_b0185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1086\/649211","article-title":"Postexposure rabies prophylaxis completed in 1 week: preliminary study","volume":"50","author":"Shantavasinkul","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2018.10.103_b0190","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1586\/14760584.7.8.1201","article-title":"Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice","volume":"7","author":"Nicolas","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.103_b0195","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/aje\/kwx234","article-title":"Rabies postexposure prophylaxis noncompletion after dog bites: estimating the unseen to meet the needs of the underserved","volume":"187","author":"Tarantola","year":"2018","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.10.103_b0200","unstructured":"WHO Expert Consultation on Rabies. 2018, World Health Organization: Geneva, Switzerland. p. 183."},{"key":"10.1016\/j.vaccine.2018.10.103_b0205","unstructured":"International Clinical Trials Registry Platform (ICTRP) \u2013 Glossary. 2018 [cited 2018 June 3]; Available from: http:\/\/www.who.int\/ictrp\/glossary\/en\/."},{"issue":"5","key":"10.1016\/j.vaccine.2018.10.103_b0210","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2217\/17460794.3.5.481","article-title":"Concepts in the pathogenesis of rabies","volume":"3","author":"Dietzschold","year":"2008","journal-title":"Future Virol"},{"issue":"18","key":"10.1016\/j.vaccine.2018.10.103_b0215","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1016\/j.vaccine.2006.02.027","article-title":"Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity","volume":"24","author":"Suwansrinon","year":"2006","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2018.10.103_b0220","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1016\/j.vaccine.2008.04.081","article-title":"Intradermal pre-exposure rabies vaccine elicits long lasting immunity","volume":"26","author":"Brown","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2018.10.103_b0225","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.trstmh.2009.03.007","article-title":"Immunogenicity and booster efficacy of pre-exposure rabies vaccination","volume":"103","author":"Strady","year":"2009","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.103_b0230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/tropej\/fmm100","article-title":"Pre-exposure purified vero cell rabies vaccine and concomitant routine childhood vaccinations: 5-year post-vaccination follow-up study of an infant cohort in Vietnam","volume":"55","author":"Lang","year":"2009","journal-title":"J Trop Pediatr"},{"key":"10.1016\/j.vaccine.2018.10.103_b0235","unstructured":"Module 17: Rabies Update 2017, in WHO Immunological Basis for Immunization Series; 2017, WHO: Geneva. p. 1\u201349."},{"issue":"S1","key":"10.1016\/j.vaccine.2018.10.103_b0240","doi-asserted-by":"crossref","first-page":"A118","DOI":"10.1016\/j.vaccine.2018.10.054","article-title":"Intradermal Rabies Post-Exposure Prophylaxis can be Abridged with No Measurable Impact on Clinical Outcome in Cambodia, 2003\u20132014","volume":"37","author":"Tarantola","year":"2019","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2018.10.103_b0245","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1164\/rccm.201303-0521OE","article-title":"Study design and \u201cevidence\u201d in patient-oriented research","volume":"187","author":"Concato","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.103_b0250","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cct.2013.09.003","article-title":"The ethics of placebo-controlled trials: methodological justifications","volume":"36","author":"Millum","year":"2013","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.103_b0255","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/sim.1425","article-title":"Non-inferiority trials: design concepts and issues \u2013 the encounters of academic consultants in statistics","volume":"22","author":"D'Agostino","year":"2003","journal-title":"Stat Med"},{"issue":"14","key":"10.1016\/j.vaccine.2018.10.103_b0260","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMra1510063","article-title":"Challenges in the design and interpretation of noninferiority trials","volume":"377","author":"Mauri","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.103_b0265","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/jme.2002.001263","article-title":"Council on, The ethics of research related to health care in developing countries","volume":"30","author":"McMillan","year":"2004","journal-title":"J Med Ethics"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.103_b0270","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/jme.2003.006031","article-title":"The standard of care debate: the Declaration of Helsinki versus the international consensus opinion","volume":"30","author":"Lie","year":"2004","journal-title":"J Med Ethics"},{"key":"10.1016\/j.vaccine.2018.10.103_b0275","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijid.2016.03.016","article-title":"Laboratory diagnostics in dog-mediated rabies: an overview of performance and a proposed strategy for various settings","volume":"46","author":"Duong","year":"2016","journal-title":"Int J Infect Dis"},{"issue":"36","key":"10.1016\/j.vaccine.2018.10.103_b0280","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1016\/j.vaccine.2015.06.101","article-title":"The weight of obesity on the human immune response to vaccination","volume":"33","author":"Painter","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.103_b0285","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/tmi.12670","article-title":"Caring for patients with rabies in developing countries \u2013 the neglected importance of palliative care","volume":"21","author":"Tarantola","year":"2016","journal-title":"Trop Med Int Health"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.103_b0290","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0264-410X(90)90123-4","article-title":"Rabies antibody profile among pregnant females administered therapeutic postexposure vaccine during pregnancy, their neonates and infants","volume":"8","author":"Arya","year":"1990","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2018.10.103_b0295","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.3201\/eid1312.070157","article-title":"Rabies prophylaxis for pregnant women","volume":"13","author":"Abazeed","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.103_b0300","first-page":"76","article-title":"Post exposure rabies prophylaxis with Purified Verocell Rabies vaccine: a study of immunoresponse in pregnant women and their matched controls","volume":"43","author":"Sudarshan","year":"1999","journal-title":"Indian J Public Health"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.103_b0305","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4269\/ajtmh.1985.34.633","article-title":"Pre-exposure rabies immunization with human diploid cell vaccine: decreased antibody responses in persons immunized in developing countries","volume":"34","author":"Bernard","year":"1985","journal-title":"Am J Trop Med Hyg"},{"issue":"8391","key":"10.1016\/j.vaccine.2018.10.103_b0310","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(84)91893-2","article-title":"Chloroquine prophylaxis associated with a poor antibody response to human diploid cell rabies vaccine","volume":"1","author":"Taylor","year":"1984","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2018.10.103_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001847","article-title":"Million Death Study, Collaborators, Deaths from symptomatically identifiable furious rabies in India: a nationally representative mortality survey","volume":"6","author":"Suraweera","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.103_b0320","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1191\/1740774504cn025oa","article-title":"Bayesian estimation of vaccine efficacy","volume":"1","author":"Chu","year":"2004","journal-title":"Clin Trials"},{"key":"10.1016\/j.vaccine.2018.10.103_b0325","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1021594923546","article-title":"Modeling clustered count data with excess zeros in health care outcomes research","volume":"3","author":"Hur","year":"2002","journal-title":"Health Services Outcomes Res Methodol"},{"key":"10.1016\/j.vaccine.2018.10.103_b0330","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/601789","article-title":"Using intradermal rabies vaccine to boost immunity in people with low rabies antibody levels","volume":"2011","author":"Brown","year":"2011","journal-title":"Adv Prev Med"},{"key":"10.1016\/j.vaccine.2018.10.103_b0335","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/403201","article-title":"Immunogenicity of simulated PCECV postexposure booster doses 1, 3, and 5 years after 2-dose and 3-dose primary rabies vaccination in schoolchildren","volume":"2011","author":"Kamoltham","year":"2011","journal-title":"Adv Prev Med"},{"issue":"9","key":"10.1016\/j.vaccine.2018.10.103_b0340","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1128\/CVI.05090-11","article-title":"Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose","volume":"18","author":"Zhang","year":"2011","journal-title":"Clin Vaccine Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18315421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18315421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:35:03Z","timestamp":1759401303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18315421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":68,"alternative-id":["S0264410X18315421"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.103","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating new rabies post-exposure prophylaxis (PEP) regimens or vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}